This technique offers an advantage over those directly targeting IGF-1R, as mAbs neutralize ligands outside the tumor microenvironment, while cell-related neutralization of the receptor allows for penetration within the tumor via receptor endocytosis and subsequent degradation in the lysosome [9]. This evidence concerns the gene IGF1R and neoplasm.